Author(s): Promrat K, Lutchman G, Uwaifo GI, Freedman RJ, Soza A, et al.
Nonalcoholic steatohepatitis (NASH) is a common chronic liver disease for which there is no known effective therapy. A proportion of patients with NASH progress to advanced fibrosis and cirrhosis. NASH is considered one of the clinical features of the metabolic syndrome in which insulin resistance plays a central role. This prospective study evaluates the role of insulin-sensitizing agent in treatment of NASH. Eighteen nondiabetic patients with biopsy-proven NASH were treated with pioglitazone (30 mg daily) for 48 weeks. Tests of insulin sensitivity and body composition as well as liver biopsies were performed before and at the end of treatment. By 48 weeks, serum alanine aminotransferase values fell to normal in 72% of patients. Hepatic fat content and size as determined by magnetic resonance imaging decreased, and glucose and free fatty acid sensitivity to insulin were uniformly improved. Histological features of steatosis, cellular injury, parenchymal inflammation, Mallory bodies, and fibrosis were significantly improved from baseline (all P < 0.05). Using strict criteria, histological improvement occurred in two-thirds of patients. Pioglitazone was well tolerated; the main side effects were weight gain (averaging 4%) and an increase in total body adiposity. In conclusion, these results indicate that treatment with an insulin-sensitizing agent can lead to improvement in biochemical and histological features of NASH and support the role of insulin resistance in the pathogenesis of this disease. The long-term safety and benefits of pioglitazone require further study.
Referred From: https://www.ncbi.nlm.nih.gov/pubmed/14752837
Author(s): Miller AM, Horiguchi N, Jeong WI, Radaeva S, Gao B
Author(s): Paula H, Asrani SK, Boetticher NC, Pedersen R, Shah VH, et al.
Author(s): Purohit V, Gao B, Song BJ
Author(s): de la Monte SM, Yeon JE, Tong M, Longato L, Chaudhry R, et al.
Author(s): Denucci SM, Tong M, Longato L, Lawton M, Setshedi M, et al.
Author(s): He J, de la Monte S, Wands JR
Author(s): Onishi Y, Honda M, Ogihara T, Sakoda H, Anai M, et al.
Author(s): Pang M, de la Monte SM, Longato L, Tong M, He J, et al.
Author(s): Ronis MJ, Wands JR, Badger TM, de la Monte SM, Lang CH, et al.
Author(s): Sasaki Y, Wands JR
Author(s): Setshedi M, Longato L, Petersen DR, Ronis M, Chen WC, et al.
Author(s): Gao B, Bataller R
Author(s): Lieber CS
Author(s): Seth D, Haber PS, Syn WK, Diehl AM, Day CP
Author(s): Setshedi M, Wands JR, Monte SM
Author(s): de la Monte SM, Longato L, Tong M, DeNucci S, Wands JR
Author(s): Mohr L, Tanaka S, Wands JR
Author(s): Friedman SL, Nieto N
Author(s): Gyamfi MA, Wan YJ
Author(s): Yessoufou A, Wahli W
Author(s): Viana Abranches M, Esteves de Oliveira FC, Bressan J
Author(s): Heald M, Cawthorne MA
Author(s): Shah P, Mudaliar S
Author(s): Phielix E, Szendroedi J, Roden M
Author(s): Tailleux A, Wouters K, Staels B
Author(s): Enomoto N, Takei Y, Hirose M, Konno A, Shibuya T, et al.
Author(s): de la Monte SM, Pang M, Chaudhry R, Duan K, Longato L, et al.
Author(s): Tomita K, Azuma T, Kitamura N, Nishida J, Tamiya G, et al.
Author(s): Pandol SJ, Gorelick FS, Gerloff A, Lugea A
Author(s): Sozio MS, Liangpunsakul S, Crabb D
Author(s): Ronis MJ, Butura A, Korourian S, Shankar K, Simpson P, et al.
Author(s): Baumgardner JN, Shankar K, Hennings L, Badger TM, Ronis MJ
Author(s): Miller AM, Wang H, Bertola A, Park O, Horiguchi N, et al.
Author(s): Carmiel-Haggai M, Cederbaum AI, Nieto N
Author(s): Bailey SM, Mantena SK, Millender-Swain T, Cakir Y, Jhala NC, et al.
Author(s): Devi SL, Anuradha CV
Author(s): Tang Y, Forsyth CB, Banan A, Fields JZ, Keshavarzian A
Author(s): Uchida T, Kao H, Quispe-Sjogren M, Peters RL
Author(s): Junge J, Horn T, Christoffersen P
Author(s): Wakabayashi T, Horiuchi M, Sakaguchi M, Onda H, Iijima M
Author(s): Rømert P, Matthiessen ME
Author(s): Rømert P, Matthiessen ME
Author(s): Ronis MJ, Butura A, Sampey BP, Shankar K, Prior RL, et al.